fcn-338
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 15, 2021 (NCT04682808)
Timeline
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06858618 | Phase 2 | Aug 16, 2023 | Fosun |
| NCT04682808 | Phase 1 | Jan 15, 2021 | Fochon Pharmaceuticals, Ltd., Sun Yat-Sen University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fochon Pharmaceuticals, Ltd. | For profit | 1 | 1 | 1 | 2021 |
| Fosun | For profit | 1 | 1 | 1 | 2023 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1